The antibody component of the drug class known as antibody-drug conjugates is directed against B-cell maturation agent (BCMA), a protein that is expressed on normal B lymphocytes and multiple myeloma cells. The small molecule component of this conjugate is monomethyl auristatin F (MMAF), a microtubule inhibitor.
When the antibody-drug conjugate binds to BCMA, the conjugate gets internalized and releases MMAF, leading to cell cycle arrest and apoptosis. It also results in tumor cell lysis though antibody-dependent cellular toxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).
Learn more about antibody-drug conjugates in multiple myeloma.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Joshua Richter. Fast Five Quiz: Multiple Myeloma Management - Medscape - May 13, 2021.
Comments